Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden administration said.

Popular weight-loss drugs like Wegovy or Ozempic would be covered by Medicare or Medicaid under a newly-proposed rule by the Biden administration.

Medicare and Medicaid would be required to cover weight loss drug prescriptions for millions of obese Americans under plans announced by the Biden administration Tuesday.

The Biden administration on Tuesday proposed requiring Medicare and Medicaid to cover weight loss drugs like Wegovy and Ozempic. Why it matters: The rule would expand access to the medications for millions of Americans struggling with obesity,

It would give millions of people access to weekly injectables that have helped people shed pounds so quickly that some people have labeled them miracle drugs.

If the proposal is finalized, it could set the stage for a showdown between the pharmaceutical industry and the Trump administration.

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more than 7 million people with Medicare and Medicaid health coverage, which could cut out-of-pocket expenses for some by as much as 95%.